An open-label phase 1 clinical trial of the anti-α4β7 monoclonal antibody vedolizumab in HIV-infected individuals
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
An open-label phase 1 clinical trial of the anti-α4β7 monoclonal antibody vedolizumab in HIV-infected individuals
Authors
Keywords
-
Journal
Science Translational Medicine
Volume 11, Issue 509, Pages eaax3447
Publisher
American Association for the Advancement of Science (AAAS)
Online
2019-09-06
DOI
10.1126/scitranslmed.aax3447
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Lack of therapeutic efficacy of an antibody to α4β7 in SIVmac251-infected rhesus macaques
- (2019) Peter Abbink et al. SCIENCE
- Evaluation of an antibody to α4β7 in the control of SIVmac239-nef-stop infection
- (2019) M. Di Mascio et al. SCIENCE
- Blocking α4β7 integrin binding to SIV does not improve virologic control
- (2019) Nami Iwamoto et al. SCIENCE
- Integrin α 4 β 7 expression on peripheral blood CD4 + T cells predicts HIV acquisition and disease progression outcomes
- (2018) Aida Sivro et al. Science Translational Medicine
- The Control of HIV after Antiretroviral Medication Pause (CHAMP) study: post-treatment controllers identified from 14 clinical studies
- (2018) Golnaz Namazi et al. JOURNAL OF INFECTIOUS DISEASES
- A randomized controlled safety/efficacy trial of therapeutic vaccination in HIV-infected individuals who initiated antiretroviral therapy early in infection
- (2017) Michael C. Sneller et al. Science Translational Medicine
- Sustained virologic control in SIV+ macaques after antiretroviral and 4 7 antibody therapy
- (2016) S. N. Byrareddy et al. SCIENCE
- Gut Epithelial Barrier Dysfunction and Innate Immune Activation Predict Mortality in Treated HIV Infection
- (2014) Peter W. Hunt et al. JOURNAL OF INFECTIOUS DISEASES
- Targeting α4β7 integrin reduces mucosal transmission of simian immunodeficiency virus and protects gut-associated lymphoid tissue from infection
- (2014) Siddappa N Byrareddy et al. NATURE MEDICINE
- In vitro assessment of the effects of vedolizumab binding on peripheral blood lymphocytes
- (2013) Tim Wyant et al. mAbs
- Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
- (2013) Brian G. Feagan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Short-Course Antiretroviral Therapy in Primary HIV Infection
- (2013) NEW ENGLAND JOURNAL OF MEDICINE
- Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
- (2013) William J. Sandborn et al. NEW ENGLAND JOURNAL OF MEDICINE
- HIV reservoirs
- (2012) Tae-Wook Chun et al. AIDS
- Vedolizumab for the Treatment of Active Ulcerative Colitis: A Randomized Controlled Phase 2 Dose-ranging Study
- (2011) Asit Parikh et al. INFLAMMATORY BOWEL DISEASES
- Blocking of 4 7 Gut-Homing Integrin during Acute Infection Leads to Decreased Plasma and Gastrointestinal Tissue Viral Loads in Simian Immunodeficiency Virus-Infected Rhesus Macaques
- (2010) A. A. Ansari et al. JOURNAL OF IMMUNOLOGY
- Antiretroviral therapy and management of HIV infection
- (2010) Paul A Volberding et al. LANCET
- Preliminary in vivo efficacy studies of a recombinant rhesus anti-α4β7 monoclonal antibody
- (2009) L.E. Pereira et al. CELLULAR IMMUNOLOGY
- The integrin 4 7 forms a complex with cell-surface CD4 and defines a T-cell subset that is highly susceptible to infection by HIV-1
- (2009) C. Cicala et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- HIV-1 envelope protein binds to and signals through integrin α4β7, the gut mucosal homing receptor for peripheral T cells
- (2008) James Arthos et al. NATURE IMMUNOLOGY
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started